Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, Cao AY, Li JJ, Yu KD, Liu GY, Wu J, Sun T, Cui JW, Lv Z, Li HP, Zhu XY, Jiang YZ, Wang ZH, Shao ZM.
Liu Y, et al. Among authors: liu gy.
Cell Res. 2023 May;33(5):389-402. doi: 10.1038/s41422-023-00795-2. Epub 2023 Mar 27.
Cell Res. 2023.
PMID: 36973538
Free PMC article.
Clinical Trial.